Published in Nat Rev Rheumatol on February 01, 2011
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis (2015) 1.69
The pathogenesis of lupus nephritis. J Am Soc Nephrol (2013) 1.33
Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol (2013) 1.27
Sequencing the functional antibody repertoire--diagnostic and therapeutic discovery. Nat Rev Rheumatol (2014) 1.20
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest (2012) 1.17
Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells. Proc Natl Acad Sci U S A (2011) 1.14
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Strategies to target long-lived plasma cells for treating hemophilia A inhibitors. Cell Immunol (2016) 1.07
Are autoantibodies the targets of B-cell-directed therapy? Nat Rev Rheumatol (2011) 1.05
Macrophages induce differentiation of plasma cells through CXCL10/IP-10. J Exp Med (2012) 1.03
Contribution of Toll-like receptor signaling to germinal center antibody responses. Immunol Rev (2012) 1.02
Immunology of IgG4-related disease. Clin Exp Immunol (2015) 1.00
Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol (2014) 1.00
Immunopathology of lupus nephritis. Semin Immunopathol (2014) 0.94
Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology (2012) 0.91
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther (2012) 0.91
Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice. Mucosal Immunol (2015) 0.91
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev (2016) 0.91
IgA response in preterm neonates shows little evidence of antigen-driven selection. J Immunol (2012) 0.90
The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol (2014) 0.90
CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther (2013) 0.90
Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol (2016) 0.90
Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res Ther (2015) 0.88
Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab. PLoS One (2014) 0.87
Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Res Ther (2012) 0.86
Rationale for B cell targeting in SLE. Semin Immunopathol (2014) 0.86
Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol (2014) 0.83
Plasma cells in immunopathology: concepts and therapeutic strategies. Semin Immunopathol (2014) 0.83
Regulation of memory CD4 T-cell pool size and function by natural killer T cells in vivo. Proc Natl Acad Sci U S A (2012) 0.83
Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice. Front Immunol (2014) 0.83
Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice. PLoS One (2015) 0.83
A Systems Biology-Based Investigation into the Pharmacological Mechanisms of Sheng-ma-bie-jia-tang Acting on Systemic Lupus Erythematosus by Multi-Level Data Integration. Sci Rep (2015) 0.82
Alterations in the peripheral blood B cell subpopulations of multidrug-resistant tuberculosis patients. Clin Exp Med (2013) 0.81
Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol (2017) 0.81
Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol (2017) 0.80
[Plasma cells]. Z Rheumatol (2015) 0.79
Persistent autoantibody-production by intermediates between short-and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullosa acquisita. PLoS One (2013) 0.77
Disruption of Splenic Lymphoid Tissue and Plasmacytosis in Canine Visceral Leishmaniasis: Changes in Homing and Survival of Plasma Cells. PLoS One (2016) 0.77
Mechanisms of Autoantibody-Induced Pathology. Front Immunol (2017) 0.76
A generalized quantitative antibody homeostasis model: antigen saturation, natural antibodies and a quantitative antibody network. Clin Transl Immunology (2017) 0.76
The flavors of plasma cells. Oncotarget (2015) 0.76
Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Dev Res (2011) 0.76
Human CD38hiCD138⁺ plasma cells can be generated in vitro from CD40-activated switched-memory B lymphocytes. J Immunol Res (2014) 0.76
γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun (2015) 0.76
[Biologics therapy for systemic lupus erythematosus. Current situation]. Z Rheumatol (2015) 0.75
[Immunological memory of the bone marrow]. Z Rheumatol (2015) 0.75
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol (2017) 0.75
Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. J Immunol (2017) 0.75
Changes in the autoantibody pattern during allogeneic stem-cell transplantation for acute myeloid leukemia complicated by systemic lupus erythematosus. Bone Marrow Transplant (2016) 0.75
Lupus nephritis: Transatlantic management recommendations compared. Nat Rev Rheumatol (2012) 0.75
Analyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy. Arthritis Res Ther (2015) 0.75
Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol (2017) 0.75
A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. J Clin Invest (2017) 0.75
Emerging Therapies for Rheumatoid Arthritis. Rheumatol Ther (2016) 0.75
Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol (2016) 0.75
Metabolic Factors that Contribute to Lupus Pathogenesis. Crit Rev Immunol (2016) 0.75
Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol (2016) 0.75
Unraveling the Role of Allo-Antibodies and Transplant Injury. Front Immunol (2016) 0.75
[B cells. Interactions and antibody production]. Z Rheumatol (2013) 0.75
Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity. Arthritis Res Ther (2017) 0.75
B cell phenotypes in patients with rheumatoid arthritis relapsing after Rituximab: Expression of B cell activating factor-binding receptors on B cell subsets. Clin Exp Immunol (2017) 0.75
[Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus]. Z Rheumatol (2016) 0.75
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci (2016) 0.75
[Therapy-resistant cells of the B cell line]. Z Rheumatol (2016) 0.75
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med (2003) 10.82
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med (2007) 6.13
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 5.22
IgE in allergy and asthma today. Nat Rev Immunol (2008) 4.67
Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell (1994) 4.60
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science (2002) 4.21
Lifetime of plasma cells in the bone marrow. Nature (1997) 3.99
Regulation of plasma-cell development. Nat Rev Immunol (2005) 3.98
Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity (2004) 3.75
Organization of immunological memory by bone marrow stroma. Nat Rev Immunol (2010) 3.57
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med (2007) 3.45
Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol (2008) 3.38
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med (2001) 3.36
On immunological memory. Annu Rev Immunol (1996) 3.21
Maintenance of serum antibody levels. Annu Rev Immunol (2005) 3.20
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood (2004) 3.17
Antigen-driven selection of virgin and memory B cells. Immunol Rev (1986) 3.10
The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J (1997) 3.09
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol (2007) 3.04
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum (2003) 3.00
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med (2008) 2.99
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 2.87
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 2.85
Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol (2011) 2.83
Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity (2007) 2.61
Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol (2003) 2.58
Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest (2005) 2.55
The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol (1981) 2.54
Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J Exp Med (2005) 2.51
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res (2007) 2.50
B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol (2006) 2.49
Autoimmunity through cytokine-induced dendritic cell activation. Immunity (2004) 2.46
Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med (2006) 2.45
Survival of long-lived plasma cells is independent of antigen. Int Immunol (1998) 2.45
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol (2008) 2.45
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 2.44
Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol (2008) 2.38
Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol (2002) 2.37
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum (2009) 2.19
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum (2006) 2.14
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum (2003) 2.03
Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol (1999) 2.03
Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum (2008) 1.99
Memory B and memory plasma cells. Immunol Rev (2010) 1.95
Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med (2005) 1.86
Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. Eur J Immunol (2001) 1.80
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum (2007) 1.79
Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A (2008) 1.75
Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol (2010) 1.73
Plasma cell differentiation and survival. Curr Opin Immunol (2008) 1.71
Humoral immunity and long-lived plasma cells. Curr Opin Immunol (2002) 1.63
Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood (2010) 1.63
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis (2007) 1.62
Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol (2009) 1.60
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood (2005) 1.51
Treatment of severe autoimmune disease by stem-cell transplantation. Nature (2005) 1.45
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis (2007) 1.42
Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol (2006) 1.35
A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum (2007) 1.31
HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis (2010) 1.30
Adaptation of humoral memory. Immunol Rev (2006) 1.29
Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation (2005) 1.29
Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation (2009) 1.26
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood (2008) 1.24
Immunoglobulin-containing cells in different lymphoid organs of the CBA mouse during its life-span. Immunology (1977) 1.17
Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome. Arthritis Rheum (1998) 1.17
Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol (2008) 1.14
Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant (2009) 1.11
IgG plasma cells display a unique spectrum of leukocyte adhesion and homing molecules. Blood (2002) 1.08
Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One (2008) 1.05
CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci U S A (2009) 1.04
Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge. J Allergy Clin Immunol (2009) 1.00
Adult stem cell transplantation in autoimmune disease. Curr Opin Hematol (2009) 0.99
Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis (2008) 0.99
Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol (2004) 0.98
Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood (2005) 0.97
Long-lived IgE- and IgG-secreting cells in rodents manifesting persistent antibody responses. Cell Immunol (1984) 0.94
Osteoclasts support the survival of human plasma cells in vitro. Int Immunol (2008) 0.87
Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells. Am J Pathol (2007) 0.87
Migration of antibody secreting cells towards CXCL12 depends on the isotype that forms the BCR. Eur J Immunol (2008) 0.85
Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells. Int J Cancer (1999) 0.83
Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood and bone marrow exhibit different phenotype and functional level of maturation. Immunology (1991) 0.83
B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis (2007) 0.83
Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc (2009) 0.82
Toward an effective targeted chemotherapy for multiple myeloma. Clin Cancer Res (2009) 0.82
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 5.22
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Organization of immunological memory by bone marrow stroma. Nat Rev Immunol (2010) 3.57
Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med (2002) 3.43
Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity (2009) 3.24
Maintenance of serum antibody levels. Annu Rev Immunol (2005) 3.20
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood (2004) 3.17
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 2.85
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol (2013) 2.81
Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity (2009) 2.73
Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity (2010) 2.59
Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol (2003) 2.58
The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol (2010) 2.53
Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol (2002) 2.37
Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 2.32
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood (2004) 2.05
Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med (2009) 2.03
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum (2008) 2.00
Memory B and memory plasma cells. Immunol Rev (2010) 1.95
Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol (2008) 1.94
Long-lived virus-reactive memory T cells generated from purified cytokine-secreting T helper type 1 and type 2 effectors. J Exp Med (2008) 1.94
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood (2008) 1.91
Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med (2003) 1.89
Antibodies and B cell memory in viral immunity. Immunity (2007) 1.86
G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood (2011) 1.82
Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol (2002) 1.80
MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A (2002) 1.79
Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol (2003) 1.74
Plasma cell differentiation and survival. Curr Opin Immunol (2008) 1.71
Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum (2004) 1.66
Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome. Arthritis Rheum (2005) 1.65
Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum (2008) 1.64
Humoral immunity and long-lived plasma cells. Curr Opin Immunol (2002) 1.63
Immunopathogenic mechanisms of systemic autoimmune disease. Lancet (2013) 1.63
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther (2011) 1.61
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood (2010) 1.57
Acute intravascular hemolysis after transfusion of a chimeric RBC unit. Transfusion (2003) 1.55
Cis- and trans-acting gene regulation is associated with osteoarthritis. Am J Hum Genet (2006) 1.55
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum (2008) 1.53
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood (2005) 1.51
Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A (2014) 1.50
Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum (2002) 1.47
Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res (2011) 1.46
Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol (2005) 1.46
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med (2010) 1.45
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
A critical control element for interleukin-4 memory expression in T helper lymphocytes. J Biol Chem (2005) 1.44
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol (2005) 1.42
Nibrin functions in Ig class-switch recombination. Proc Natl Acad Sci U S A (2005) 1.41
A serologic marker for fetal risk of congenital heart block. Arthritis Rheum (2002) 1.38
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A (2009) 1.38
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis (2011) 1.37
Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol (2006) 1.35
Digital NFATc2 activation per cell transforms graded T cell receptor activation into an all-or-none IL-2 expression. PLoS One (2007) 1.35
Plasma cells for a lifetime? Eur J Immunol (2002) 1.35
The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Res Ther (2005) 1.34
Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur J Immunol (2007) 1.34
B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol (2009) 1.32
IFN-γ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol (2010) 1.31
Adaptation of humoral memory. Immunol Rev (2006) 1.29
Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med (2009) 1.27
Type II membrane protein CD69 regulates the formation of resting T-helper memory. Proc Natl Acad Sci U S A (2012) 1.26
Small but mighty: how the MACS-technology based on nanosized superparamagnetic particles has helped to analyze the immune system within the last 20 years. Cytometry A (2010) 1.26
1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur J Immunol (2008) 1.25
GATA-3 transcriptional imprinting in Th2 lymphocytes: a mathematical model. Proc Natl Acad Sci U S A (2002) 1.23
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Cytokine memory of T helper lymphocytes. Adv Immunol (2002) 1.22
Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. J Immunol (2010) 1.20
Organization and maintenance of immunological memory by stroma niches. Eur J Immunol (2009) 1.19
Short-term memory in gene induction reveals the regulatory principle behind stochastic IL-4 expression. Mol Syst Biol (2010) 1.19
New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. Curr Opin Rheumatol (2003) 1.19
Visualization of peptide presentation following oral application of antigen in normal and Peyer's patches-deficient mice. Eur J Immunol (2003) 1.19
Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis (2012) 1.18
B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.18